Optimizing Transition of Care in Multiple Myeloma: Bridging the Gap Between Academic and Community Settings : Episode 3
CAR T-Cell Therapy: Leukapheresis Practices
Myeloma specialists discuss their approaches to determining the optimal timing for leukapheresis for patients awaiting CAR T-cell therapy.
- What are the criteria used to determine the optimal timing for leukapheresis in relation to the bridging therapy regimen and disease burden?
- How is the leukapheresis procedure scheduled and coordinated between the community oncologist and the academic CAR-T center?
- How are patients monitored after leukapheresis while awaiting CAR-T manufacturing and infusion?
Recent Videos
Related Content
